Some results came from a study of adolescents by the National Institute of Mental Health and the rest came from two drug makers, Eli Lilly, which markets Prozac, and Wyeth, whose parent company markets Effexor. The authors have served as consultants or...

Qnexa's other ingredient, phentermine, was one half of the dangerous fen-phen combination, a weight loss treatment pushed by doctors that was never approved by the FDA. The regimen was linked to heart-valve damage and lung problems in the late 1990s,...

Reacting to the news, the company's shares opened the day on a bearish note and finally ended at Rs 541.45, down 2.49 per cent from the previous on the BSE. On the NSE also, the stock settled 2.81 per cent lower at Rs 541.05. Sun Pharma late on...

Under that plan, it would take 10 years for the soil to be cleaned up, and 30 years for the groundwater to be pollution-free. Pfizer inherited the 435-acre property in 2009 as part of its purchase of Wyeth Holding Corporation, which owned the site at...

Protonix at-risk in December 2007 and Watson Pharma launched the authorised generic in 2008. Subsequently, Sun Pharma launched the product in the same year. These generic launches happened when a US Court did not conclude that the patent on Protonix was...

Shares of Sun Pharmaceutical Industries ended lower on Indian bourses after the firm said that Wyeth was claiming damages of $960 million in a case concerning generic Protonix (pantoprazole), though analysts believe that the "exaggerated" claim was...

Wyeth's brand-name Protonix sales hit $1.9 billion in 2007, then dropped by 58% in 2008 after Sun and rival generics maker Teva Pharmaceutical Industries ($TEVA) launched their versions. The $960 million claim includes lost sales, litigation costs and...

Polyneuropathy, a rare neurodegenerative disease also known as TTR-FAP. The FDA decision was revealed one day after Pfizer’s research-and-development chief, Mikael Dolsten, told an investor conference in New York City that its experimental medication...

Sun Pharma with a price target of Rs 534 as against the current market price (CMP) of Rs 555 in its report dated Feb. 16, 2012. The broking house gave the following rationale: Sun Pharma has announced that in the on-going patent litigation on generic...

US-based Wyeth Pharmaceuticals has sought damages related to their ongoing patent dispute over a generic version of Protonix drug. Protonix is a registered trademark of Wyeth, which was acquired by Pfizer in 2009. In a regulatory filing issued after the...

Protonix was a top-selling drug for Wyeth, which was acquired by Pfizer in 2009. Wyeth and Nycomed -- the company from which it licensed the Protonix patent -- had filed patent-infringement suits against Teva and Sun Pharma in 2004, seeking to block...

Sun fell 2.8 percent to 541.15 rupees, poised for its steepest fall since Nov. 16, after declining as much as 3.9 percent at 11:40 a.m. in Mumbai. The stock was the biggest loser in the 19-company BSE Healthcare Index. (BSETHC) Sun and Teva...

Wednesday said Wyeth Pharmaceuticals Inc. is claiming damages of $960 million in a patent dispute over a generic version of the heartburn drug Protonix. Wyeth is a unit of Pfizer Inc. BANGALORE – India's Sun Pharmaceutical Industries Ltd. Wednesday...

Earlier in 2010, the District Court had denied defendants motion for judgment as a matter of law seeking to reverse the jury verdict that the patent is not invalid. The District Court is yet to rule on patent misuse. Wyeth`s experts have estimated the...

Mumbai: Wyeth Pharmaceuticals Inc is seeking $960 million in damages from Sun Pharmaceutical Industries for alleged patent infringement in launching a generic version of acid reflux drug Protonix in the United States, the Indian company said. The...

Net profit for December quarter 2011 stood at Rs 365.23 crore versus Rs 342.67 crore, posted in the period a year ago. Below is the edited transcript of Baldota's interview with CNBC-TV18. Also watch the accompanying video. Q: Can you talk about the...

Like this video, share it with millions of investors on M3 Post your opinion here Keep me signed in Trader Atul Suri says the Nifty crossing 5100 was an important turning point for the market.... Share this video with Friends it is sure that indian...

The stock opened at Rs 537 levels and touched a low of Rs 535 in trades thus far on the Bombay Stock Exchange (BSE). As many as 57,400 shares have changed hands till 951am on the BSE. Sun Pharma is trading nearly 3% lower at Rs 540 levels on reports...

"Sun Pharma believes that it has sound reasons to disagree with these overstated claims of Wyeth, and also continues to believe that the patent is invalid and unenforceable and will pursue all available legal remedies including appeals," the company...